Toll Free: 1-888-928-9744

Myelodysplastic Syndrome - Pipeline Review, H1 2016

Published: May 25, 2016 | Pages: 784 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Myelodysplastic Syndrome - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Myelodysplastic Syndrome - Pipeline Review, H1 2016', provides an overview of the Myelodysplastic Syndrome pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome
- The report reviews pipeline therapeutics for Myelodysplastic Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Myelodysplastic Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Myelodysplastic Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Myelodysplastic Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 7 Myelodysplastic Syndrome Overview 8 Therapeutics Development 9 Myelodysplastic Syndrome - Therapeutics under Development by Companies 11 Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes 18 Myelodysplastic Syndrome - Pipeline Products Glance 19 Myelodysplastic Syndrome - Products under Development by Companies 22 Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes 31 Myelodysplastic Syndrome - Companies Involved in Therapeutics Development 32 Myelodysplastic Syndrome - Therapeutics Assessment 124 Drug Profiles 146 Myelodysplastic Syndrome - Recent Pipeline Updates 467 Myelodysplastic Syndrome - Dormant Projects 752 Myelodysplastic Syndrome - Discontinued Products 758 Myelodysplastic Syndrome - Product Development Milestones 760 Appendix 767
List of Tables
Number of Products under Development for Myelodysplastic Syndrome, H1 2016 25 Number of Products under Development for Myelodysplastic Syndrome - Comparative Analysis, H1 2016 26 Number of Products under Development by Companies, H1 2016 27 Number of Products under Development by Companies, H1 2016 (Contd..1) 28 Number of Products under Development by Companies, H1 2016 (Contd..2) 29 Number of Products under Development by Companies, H1 2016 (Contd..3) 30 Number of Products under Development by Companies, H1 2016 (Contd..4) 31 Number of Products under Development by Companies, H1 2016 (Contd..5) 32 Number of Products under Development by Companies, H1 2016 (Contd..6) 33 Number of Products under Investigation by Universities/Institutes, H1 2016 34 Comparative Analysis by Late Stage Development, H1 2016 35 Comparative Analysis by Clinical Stage Development, H1 2016 36 Comparative Analysis by Early Stage Development, H1 2016 37 Products under Development by Companies, H1 2016 38 Products under Development by Companies, H1 2016 (Contd..1) 39 Products under Development by Companies, H1 2016 (Contd..2) 40 Products under Development by Companies, H1 2016 (Contd..3) 41 Products under Development by Companies, H1 2016 (Contd..4) 42 Products under Development by Companies, H1 2016 (Contd..5) 43 Products under Development by Companies, H1 2016 (Contd..6) 44 Products under Development by Companies, H1 2016 (Contd..7) 45 Products under Development by Companies, H1 2016 (Contd..8) 46 Products under Investigation by Universities/Institutes, H1 2016 47 Myelodysplastic Syndrome - Pipeline by 4SC AG, H1 2016 48 Myelodysplastic Syndrome - Pipeline by Acceleron Pharma, Inc., H1 2016 49 Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 50 Myelodysplastic Syndrome - Pipeline by Aeglea BioTherapeutics, Inc., H1 2016 51 Myelodysplastic Syndrome - Pipeline by Agios Pharmaceuticals, Inc., H1 2016 52 Myelodysplastic Syndrome - Pipeline by Altor BioScience Corporation, H1 2016 53 Myelodysplastic Syndrome - Pipeline by Amgen Inc., H1 2016 54 Myelodysplastic Syndrome - Pipeline by Apogenix GmbH, H1 2016 55 Myelodysplastic Syndrome - Pipeline by Arno Therapeutics, Inc., H1 2016 56 Myelodysplastic Syndrome - Pipeline by Arog Pharmaceuticals, Inc., H1 2016 57 Myelodysplastic Syndrome - Pipeline by Array BioPharma Inc., H1 2016 58 Myelodysplastic Syndrome - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 59 Myelodysplastic Syndrome - Pipeline by Atara Biotherapeutics, Inc., H1 2016 60 Myelodysplastic Syndrome - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 61 Myelodysplastic Syndrome - Pipeline by Bio-Path Holdings, Inc., H1 2016 62 Myelodysplastic Syndrome - Pipeline by BioLineRx, Ltd., H1 2016 63 Myelodysplastic Syndrome - Pipeline by BioLite, Inc., H1 2016 64 Myelodysplastic Syndrome - Pipeline by Boehringer Ingelheim GmbH, H1 2016 65 Myelodysplastic Syndrome - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2016 66 Myelodysplastic Syndrome - Pipeline by Boston Biomedical, Inc., H1 2016 67 Myelodysplastic Syndrome - Pipeline by Bristol-Myers Squibb Company, H1 2016 68 Myelodysplastic Syndrome - Pipeline by Cantex Pharmaceuticals, Inc., H1 2016 69 Myelodysplastic Syndrome - Pipeline by Celator Pharmaceuticals, Inc., H1 2016 70 Myelodysplastic Syndrome - Pipeline by Celgene Corporation, H1 2016 71 Myelodysplastic Syndrome - Pipeline by Celldex Therapeutics, Inc., H1 2016 72 Myelodysplastic Syndrome - Pipeline by Cellerant Therapeutics, Inc., H1 2016 73 Myelodysplastic Syndrome - Pipeline by Celyad SA, H1 2016 74 Myelodysplastic Syndrome - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016 75 Myelodysplastic Syndrome - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016 76 Myelodysplastic Syndrome - Pipeline by CrystalGenomics, Inc., H1 2016 77 Myelodysplastic Syndrome - Pipeline by CTI BioPharma Corp., H1 2016 78 Myelodysplastic Syndrome - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 79 Myelodysplastic Syndrome - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 80 Myelodysplastic Syndrome - Pipeline by DiNonA Inc., H1 2016 81 Myelodysplastic Syndrome - Pipeline by Eisai Co., Ltd., H1 2016 82 Myelodysplastic Syndrome - Pipeline by Eleos Inc., H1 2016 83 Myelodysplastic Syndrome - Pipeline by Eli Lilly and Company, H1 2016 84 Myelodysplastic Syndrome - Pipeline by EpiZyme, Inc., H1 2016 85 Myelodysplastic Syndrome - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 86 Myelodysplastic Syndrome - Pipeline by FORMA Therapeutics, Inc., H1 2016 87 Myelodysplastic Syndrome - Pipeline by Fujifilm Corporation, H1 2016 88 Myelodysplastic Syndrome - Pipeline by H3 Biomedicine Inc., H1 2016 89 Myelodysplastic Syndrome - Pipeline by IGF Oncology, LLC., H1 2016 90 Myelodysplastic Syndrome - Pipeline by ImmunoGen, Inc., H1 2016 91 Myelodysplastic Syndrome - Pipeline by Incyte Corporation, H1 2016 92 Myelodysplastic Syndrome - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2016 93 Myelodysplastic Syndrome - Pipeline by Johnson & Johnson, H1 2016 94 Myelodysplastic Syndrome - Pipeline by Juno Therapeutics Inc., H1 2016 95 Myelodysplastic Syndrome - Pipeline by JW Pharmaceutical Corporation, H1 2016 96 Myelodysplastic Syndrome - Pipeline by Kainos Medicine, Inc., H1 2016 97 Myelodysplastic Syndrome - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016 98 Myelodysplastic Syndrome - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 99 Myelodysplastic Syndrome - Pipeline by Kiadis Pharma B.V., H1 2016 100 Myelodysplastic Syndrome - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 101 Myelodysplastic Syndrome - Pipeline by La Jolla Pharmaceutical Company, H1 2016 102 Myelodysplastic Syndrome - Pipeline by Les Laboratoires Servier SAS, H1 2016 103 Myelodysplastic Syndrome - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016 104 Myelodysplastic Syndrome - Pipeline by MacroGenics, Inc., H1 2016 105 Myelodysplastic Syndrome - Pipeline by medac GmbH, H1 2016 106 Myelodysplastic Syndrome - Pipeline by MedImmune, LLC, H1 2016 107 Myelodysplastic Syndrome - Pipeline by MEI Pharma, Inc., H1 2016 108 Myelodysplastic Syndrome - Pipeline by Merck & Co., Inc., H1 2016 109 Myelodysplastic Syndrome - Pipeline by Merus B.V., H1 2016 110 Myelodysplastic Syndrome - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 111 Myelodysplastic Syndrome - Pipeline by Mirati Therapeutics Inc., H1 2016 112 Myelodysplastic Syndrome - Pipeline by Mirna Therapeutics, Inc., H1 2016 113 Myelodysplastic Syndrome - Pipeline by Nemucore Medical Innovations, Inc., H1 2016 114 Myelodysplastic Syndrome - Pipeline by Novartis AG, H1 2016 115 Myelodysplastic Syndrome - Pipeline by Onconova Therapeutics, Inc., H1 2016 116 Myelodysplastic Syndrome - Pipeline by Opsona Therapeutics Limited, H1 2016 117 Myelodysplastic Syndrome - Pipeline by OXiGENE, Inc., H1 2016 118 Myelodysplastic Syndrome - Pipeline by Pfizer Inc., H1 2016 119 Myelodysplastic Syndrome - Pipeline by Pharma Mar, S.A., H1 2016 120 Myelodysplastic Syndrome - Pipeline by Plexxikon Inc., H1 2016 121 Myelodysplastic Syndrome - Pipeline by Polyphor Ltd., H1 2016 122 Myelodysplastic Syndrome - Pipeline by Regen BioPharma, Inc., H1 2016 123 Myelodysplastic Syndrome - Pipeline by Rich Pharmaceuticals, Inc., H1 2016 124 Myelodysplastic Syndrome - Pipeline by Seattle Genetics, Inc., H1 2016 125 Myelodysplastic Syndrome - Pipeline by Stemline Therapeutics, Inc., H1 2016 126 Myelodysplastic Syndrome - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 127 Myelodysplastic Syndrome - Pipeline by Sunesis Pharmaceuticals, Inc., H1 2016 128 Myelodysplastic Syndrome - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016 129 Myelodysplastic Syndrome - Pipeline by Synta Pharmaceuticals Corp., H1 2016 130 Myelodysplastic Syndrome - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 131 Myelodysplastic Syndrome - Pipeline by Targazyme, Inc., H1 2016 132 Myelodysplastic Syndrome - Pipeline by TetraLogic Pharmaceuticals, H1 2016 133 Myelodysplastic Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 134 Myelodysplastic Syndrome - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 135 Myelodysplastic Syndrome - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2016 136 Myelodysplastic Syndrome - Pipeline by Tolero Pharmaceuticals, Inc., H1 2016 137 Myelodysplastic Syndrome - Pipeline by Tragara Pharmaceuticals, Inc., H1 2016 138 Myelodysplastic Syndrome - Pipeline by Trillium Therapeutics Inc., H1 2016 139 Assessment by Monotherapy Products, H1 2016 140 Assessment by Combination Products, H1 2016 141 Number of Products by Stage and Target, H1 2016 143 Number of Products by Stage and Mechanism of Action, H1 2016 152 Number of Products by Stage and Route of Administration, H1 2016 159 Number of Products by Stage and Molecule Type, H1 2016 161 Myelodysplastic Syndrome Therapeutics - Recent Pipeline Updates, H1 2016 483 Myelodysplastic Syndrome - Dormant Projects, H1 2016 768 Myelodysplastic Syndrome - Dormant Projects (Contd..1), H1 2016 769 Myelodysplastic Syndrome - Dormant Projects (Contd..2), H1 2016 770 Myelodysplastic Syndrome - Dormant Projects (Contd..3), H1 2016 771 Myelodysplastic Syndrome - Dormant Projects (Contd..4), H1 2016 772 Myelodysplastic Syndrome - Dormant Projects (Contd..5), H1 2016 773 Myelodysplastic Syndrome - Discontinued Products, H1 2016 774 Myelodysplastic Syndrome - Discontinued Products (Contd..1), H1 2016 775


List of Figures
Number of Products under Development for Myelodysplastic Syndrome, H1 2016 25 Number of Products under Development for Myelodysplastic Syndrome - Comparative Analysis, H1 2016 26 Number of Products under Development by Companies, H1 2016 27 Number of Products under Investigation by Universities/Institutes, H1 2016 34 Comparative Analysis by Late Stage Development, H1 2016 35 Comparative Analysis by Clinical Stage Development, H1 2016 36 Comparative Analysis by Early Stage Products, H1 2016 37 Assessment by Monotherapy Products, H1 2016 140 Number of Products by Top 10 Targets, H1 2016 142 Number of Products by Stage and Top 10 Targets, H1 2016 142 Number of Products by Top 10 Mechanism of Actions, H1 2016 151 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 151 Number of Products by Routes of Administration, H1 2016 158 Number of Products by Stage and Routes of Administration, H1 2016 158 Number of Products by Top 10 Molecule Types, H1 2016 160 Number of Products by Stage and Top 10 Molecule Types, H1 2016 160

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in c

Read More...

Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certain

Read More...

Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from main

Read More...

Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commerc

Read More...

Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population i

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify